Celcuity earnings release, May 14, 2026

Celcuity Inc. (CELC) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Celcuity

Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

MINNEAPOLIS,

May 14, 2026 — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the first quarter ended March 31, 2026 and other recent business developments.

“With positive results in both cohorts of the pivotal VIKTORIA-1 study, we believe gedatolisib regimens have the potential to advance the standard of care in the second-line setting for a significant number of patients with

HR+/HER2- advanced breast cancer, regardless of

PIK3CA status,” said Brian Sullivan, CEO and co-founder of Celcuity. “We are on track to launch gedatolisib commercially in anticipation of its potential FDA approval in the third quarter of 2026, and we look forward to bringing this important therapy to physicians treating patients with advanced breast cancer.”

Mr.

Sullivan added, “Our positive Phase 3 results, combined with our promising Phase 1b clinical trial results in treatment-naive late-stage patients, provide a strong scientific rationale to evaluate gedatolisib combinations as first-line therapy. By expanding our

VIKTORIA-2 study to enable evaluation of treatment-naive patients who have endocrine-sensitive breast cancer, we are positioning gedatolisib regimens to potentially be available for nearly all patients in the first-line setting, irrespective of their endocrine sensitivity or

PIK3CA status.”

First

Quarter 2026 Business Highlights and Other Recent Developments

First

Quarter 2026 Financial Results

Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2026, compared to the first quarter ended March 31, 2025.

Net loss for the first quarter of 2026 was $52.8 million, or $0.97 per share, compared to a net loss of $37.0 million, or $0.86 per share, for the first quarter of 2025. Non-GAAP adjusted net loss for the first quarter of 2026 was $46.8 million, or $0.86 per share, compared to non-GAAP adjusted net loss of $34.7 million, or $0.81 per share, for the first quarter of 2025. Non-GAAP adjusted net loss excludes stock-based compensation expense, non-cash interest expense, and non-cash interest income. Because these items have no impact on Celcuity’s cash position, management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations. For a reconciliation of financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”) to non-GAAP financial measures, please see the financial tables at the end of this press release.

Total operating expenses were $50.5 million for the first quarter of 2026, compared to $36.1 million for the first quarter of 2025.

Research and development (“R&D”) expenses were $33.1 million for the first quarter of 2026, compared to $29.8 million for the prior year period.

The

$3.3 million increase in R&D expenses was primarily due to a

$3.0 million increase in employee-related and consulting expenses. The remaining increase was primarily due to a $5.4 million increase in manufacturing and other costs, partially offset by a $5.1 million decrease in clinical trial costs, which was primarily driven by decreased costs for the VIKTORIA-1

Phase 3 clinical trial.

Selling, general and administrative (“SG&A”) expenses were $17.4 million for the first quarter of 2026, compared to $6.3 million for the prior year period.

The

$11.1 million increase in SG&A expenses was primarily due to an

$8.7 million increase in employee-related and consulting expenses, of which $6.6 million was due to commercial headcount additions and other launch-related activities, and a $2.4 million increase primarily due to software costs, professional fees and other costs.

Net cash used in operating activities for the first quarter of 2026 was $55.1 million, compared to $35.9 million for the prior year period.

Cash, cash equivalents and short-term investments were $387.1 million at the end of the first quarter of 2026. We expect cash, cash equivalents, investments and drawdowns on our debt facility to finance our operations through 2027.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865.

A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1760785&tp_key=2f73ec65ba.

A replay of the webcast will be available on the Celcuity website following the live event.

About

Celcuity

Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR (“PAM”) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. Our Phase 3 clinical trial,

VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, has reported detailed results for Study 1, which evaluated patients with

PIK3CA

WT tumors, and announced topline results for Study 2, which evaluated patients with

PIK3CA

MT tumors. Our Phase 3 clinical trial, VIKTORIA-2, is ongoing and incorporates two independent... (truncated) ABC who are treatment-naive in the advanced setting.

Study 1 is evaluating gedatolisib combined with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant

HR+/HER2- ABC. Study 2 is evaluating gedatolisib combined with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive

HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at

ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Follow us on

LinkedIn and

X.

Forward

Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (in thousands, except share and per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating expenses:Research and development (1)33,06329,759
Operating expenses:Selling, general and administrative (1)17,4446,374
Operating expenses:Total operating expenses50,50736,133
Operating expenses:Loss from operations-50,507-36,133
Other (expense) income:Interest expense-6,085-3,183
Other (expense) income:Interest income3,7512,319
Other (expense) income:Other (expense) income, net-2,334-864
Other (expense) income:Net loss before income taxes-52,841-36,997
Other (expense) income:Net loss-52,841-36,997
Other (expense) income:Net loss per share, basic and diluted-0.97-0.86
Other (expense) income:Weighted average common shares outstanding, basic and diluted54,462,82643,052,757

Income Statement

Three Months Ended March 31, — (in thousands, except share and per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
GAAP net loss-52,841-36,997
Stock-based compensationResearch and development (1), (2)2,1121,164
Stock-based compensationSelling, general and administrative (1), (3)3,2131,280
Stock-based compensationNon-cash interest expense (4)1,577800
Stock-based compensationNon-cash interest income (5)-883-946
Stock-based compensationNon-GAAP adjusted net loss-46,822-34,699
Stock-based compensationGAAP net loss per share - basic and diluted-0.97-0.86
Stock-based compensationResearch and development0.040.02
Stock-based compensationSelling, general and administrative0.060.03
Stock-based compensationNon-cash interest expense0.030.02
Stock-based compensationNon-cash interest income-0.02-0.02
Stock-based compensationNon-GAAP adjusted net loss per share - basic and diluted-0.86-0.81
Stock-based compensationWeighted average common shares outstanding, basic and diluted54,462,82643,052,757

Balance Sheet

March 31, 2026 — (in thousands)

March 31, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents145,191165,703
Current assets:Investments241,873275,794
Current assets:Other current assets21,86524,162
Current assets:Total current assets408,929465,659
Current assets:Property and equipment, net619499
Current assets:Operating lease right-of-use assets1351
Current assets:Other non-current assets603349
Current assets:Total assets410,164466,558
Current liabilities:Accounts payable10,4546,407
Current liabilities:Accrued expenses22,74437,691
Current liabilities:Operating lease liabilities, current1354
Current liabilities:Total current liabilities33,21144,152
Current liabilities:Convertible notes195,566195,324
Current liabilities:Note payable127,862126,527
Current liabilities:Total liabilities356,639366,003
Current liabilities:Total stockholders’ equity53,525100,555
Current liabilities:Total liabilities and stockholders’ equity410,164466,558
Full release

This press release contains statements that constitute “forward-looking statements” within the meaning of the Private Securities

Litigation Reform Act of 1995 including statements relating to the potential therapeutic benefits of gedatolisib; the size, design and timing of our clinical trials; our interpretation of clinical trial data; the status and timing of the FDA’s review of our NDA for gedatolisib, including the PDUFA goal date assigned by the FDA; the ability of our data to support the filing of an sNDA with the

FDA and comparable filings with other regulatory authorities outside the U.S.; our intent to present data at the 2026 ASCO Annual Meeting; the market opportunity for gedatolisib; our expectations regarding the timing of and our ability to obtain FDA approval to commercialize gedatolisib; our strategy, marketing and commercialization plans, including the benefits of strategic decisions regarding studies and trials; other expectations with respect to gedatolisib, including subcutaneous formulations to support potential future indications for gedatolisib regimens; our anticipated use of cash; and the strength of our balance sheet. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,”

“confidence,” “encouraged,” “potential,” “plan,” “targets,” “likely,”

“may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management’s current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including that our topline clinical results are based on an ongoing analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial; unforeseen delays in our clinical trials or the FDA’s review of our NDA for gedatolisib; our ability to obtain and maintain regulatory approvals to commercialize gedatolisib, and the market acceptance of gedatolisib; the development of therapies and tools competitive with gedatolisib; and our ability to access capital upon favorable terms. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the

Securities and Exchange Commission on March 26, 2026, as such risks may be updated in our subsequent filings with the Securities and

Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

References:

1.

Internal estimates using data from National Cancer Institute, SEER, 2024; Pan, H, NEJM, 2017;377:1836-46; Dowsett, M 2009; Salvo, E.

M. et al. 2021

Contacts:

Celcuity

Inc.

Brian

Sullivan, bsullivan@celcuity.com

Vicky

Hahne, vhahne@celcuity.com

(763)

392-0123

Jodi

Sievers, jsievers@celcuity.com

(415)

494-9924

Celcuity

Inc.

Condensed

Balance Sheets

(in thousands)

Celcuity

Inc.

Condensed

Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)

Cautionary

Statement Regarding Non-GAAP Financial Measures

This press release contains references to non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Management believes these non-GAAP financial measures are useful supplemental measures for planning, monitoring, and evaluating operational performance as they exclude stock-based compensation expense, non-cash interest expense, and non-cash interest income from net loss and net loss per share. Management excludes these items because they do not impact Celcuity’s cash position, which management believes better enables Celcuity to focus on cash used in operations. However, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP. As a result, management’s method of calculating non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may differ materially from the method used by other companies. Therefore, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may not be comparable to similarly titled measures presented by other companies. Investors are cautioned that non-GAAP adjusted net loss and non-GAAP adjusted net loss per share should not be construed as alternatives to net loss, net loss per share or other statements of operations data (which are determined in accordance with GAAP) as an indicator of Celcuity’s performance or as a measure of liquidity and cash flows.

Celcuity

Inc.

Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and

GAAP

Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share

(unaudited)

(in... (truncated) amounts)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Celcuity earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.